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Abstract
Spray-drying allows to modify the physicochemical/mechanical properties of particles along with their morphology. In the
present study, L-leucine with varying concentrations (0.1, 0.5, 1, 5, and 10% w/v) were incorporated into lactose monohydrate
solution for spray-drying to enhance the aerosolization performance of dry powder inhalers containing spray-dried lactose-
leucine and salbutamol sulfate. The prepared spray-dried lactose-leucine carriers were analyzed using laser diffraction (particle
size), differential scanning calorimetry (thermal behavior), scanning electron microscopy (morphology), powder X-ray diffrac-
tion (crystallinity), Fourier transform infrared spectroscopy (interaction at molecular level), and in vitro aerosolization perfor-
mance (deposition). The results showed that the efficacy of salbutamol sulfate’s aerosolization performance was, in part, due to
the introduction of L-leucine in the carrier, prior to being spray-dried, accounting for an increase in the fine particle fraction (FPF)
of salbutamol sulfate from spray-dried lactose-leucine (0.5% leucine) in comparison to all other carriers. It was shown that all of
the spray-dried carriers were spherical in their morphology with some agglomerates and contained a mixture of amorphous, α-
lactose, and β-lactose. It was also interesting to note that spray-dried lactose-leucine particles were agglomerated during the
spray-drying process to make coarse particles (volume mean diameter of 79 to 87 μm) suitable as a carrier in DPI formulations.
Keywords Dry powder inhaler . Spray-drying . Agglomeration . Salbutamol sulfate . Leucine
Introduction
Using the pulmonary tract as an avenue for the administration
of therapeutic agents to tackle chronic obstructive pulmonary
disease (COPD), asthma, bronchitis, and cystic fibrosis are
just a few examples of how the route of inhalation is used in
a systematic fashion for drug delivery [1]. Tackling the disad-
vantages faced by dry powder inhalers (DPIs) begins with
selecting a carrier such that it provides a good delivery of
the active pharmaceutical ingredient (API) of interest [2–7].
The chosen carrier does not only need to be safe and cost-
effective, and pass strict pharmacopeia guidelines, but, more
importantly, it needs to be selected in such a manner that it
adheres to chemical properties that will not interfere with the
drug delivery process and that complement the API chosen [5,
8–13].
To date, lactose is the most commonly documented carrier
in the pharmaceutical industry due to being highly stable,
adhering to good flow properties, and being widely accepted
as a safe excipient for use [13]. Although other carriers such as
mannitol [14] and sorbitol [15] as well as other sugars [15]
have been suggested in DPI formulations, lactose is still the
only excipient approved by the FDA in DPI formulations of
APIs. At the present, the focus is to engineer carrier particles
with modified physicochemical properties to promote the
aerosolization of APIs to penetrate the deeper regions of the
lungs [16].
The use of leucine has previously been shown to improve
the aerosolization performance of several drugs from DPIs
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[17–19] because it reduces the inter-particulate adhesive
forces and API aerodynamic particle size due to its surfactant
behavior [20]. For example, leucine has been proven benefi-
cial on Naringin dry powder as it has enhanced aerosol per-
formance while improving the activity of cystic fibrosis air-
way epithelial cells [21].
It is recognized that lactose particles classified with being
more elongated, being more irregular in shape, and having a
rougher surface are exponentially preferred [14].
Consequently, the epitome of this overall study begins with
using lactose monohydrate as a carrier of salbutamol sulfate
with increasing leucine concentrations to manufacture an ag-
glomerate spray-dried lactose-leucine system that will en-
hance the performance of salbutamol sulfate from DPI formu-
lations. On the basis of this, the aim of the current research
work was to investigate the effect of leucine on the perfor-
mance of spray-dried lactose-leucine in DPI containing
salbutamol sulfate.
Materials and methods
Materials
α-Lactose monohydrate (DFE Pharma, Gosh, Germany, puri-
ty 99 +%; lactose is one of the main excipients approved to be
used in DPI formulation), salbutamol sulfate (L.B. Bohle,
Germany; purity 99%), and L-leucine (Acros Organics, Geel,
Belgium, purity 99 +%; it is used as anti-adherent and lubri-
cant) were used in their purest form. Monobasic potassium
phosphate (Fisher Scientific, UK) was used for the preparation
of the mobile phase for high-pressure liquid chromatography
(HPLC). All solvents (methanol, ethanol, and hydrochloric
acid) were purchased from VWR International Ltd.
(Leighton Buzzard, UK) and were of HPLC grade.
Spray-drying
Spray-drying was conducted using the Mini Spray Dryer B-
290 from Buchi (Flawil, Switzerland) equipped with a dehu-
midifier (Dehumidifier B-296), an inert loop (Inert Loop
B-295), and an outlet filter. The parameters associated with
the procedure were as follows: inlet temperature of 220 °C,
aspirator set to 100%, pump rate set to 5%, and a flow rate of
22% designed for a closed environment with the use of nitro-
gen (N2) gas.
Each 100 mL of the solution for spray-drying contained
different concentrations of leucine (0.1, 0.5, 1, 5, and 10 g)
and 60 g of lactose. That means the percentage of leucine in
each solution was 0.1, 0.5, 1, 5, and 10% w/v, respectively.
Both leucine and lactose were dissolved in distilled water
while heating the solution to 75 °C with a stirring speed of
120 rpm. The final solutions were spray-dried under the con-
ditions mentioned above.
Sieving
A Retsch AS 200 Digit Analytical Sieve Shaker (Hoan,
Germany) was used to separate particle sizes within the 63–
90-μm range (this is the standard particle size range for car-
riers that are used in DPI formulations). The collection pan
was placed at the bottom, which was then followed by the
63-μm sieving pan, and finishing with the 90-μm sieving
pan. The spray-dried particles were placed on top of the
90-μm sieving pan where sieving was performed for 30 min
with an amplitude of 100 for each of the carriers. Particles that
fell within the 63–90-μm range were collected in glass vials,
sealed, and stored in an air-conditioned laboratory at a set
temperature of 20 °C and a relative humidity (RH) of 50%
for future use within this study.
Particle size distribution analysis
Particle size distribution analysis was conducted using a laser
diffraction particle size analyzer. The laser diffraction particle
size analyzer (Sympatec Ltd., UK) is equipped with the
HELOS sensor and Windox software and was used in combi-
nation with the RODOS (dry) system and Cuvette (wet) sys-
tem; the wet system used absolute ethanol, a stirring speed of
1200 rpm, and 20 s of sonication. Detecting the particles was
done using the R3 and R5 lenses, which have a particle size
detection range of 0.5–175 and 0.5–875 μm, respectively.
The span of size distribution was calculated by Eq. 1:
Span ¼ D90%−D10%ð Þ=D50% ð1Þ
where D90%, D50%, and D10% refer to the particle size (in
μm) of 90, 50, and 10% of the cumulative particle size distri-
bution, respectively.
Preparation of DPI formulations
To the stored 63–90-μm sieved carriers, salbutamol sulfate
(SS) was added such that a final ratio of 67.5:1 (Carrier: SS)
was obtained. To prepare the final formulation, 1.35 g of each
carrier was mixed with 20 mg SS using a Turbula blender
(Type T2F, Junkermattstrasse, Switzerland) where each of
the formulations was subjected to 30 min of blending at a
speed of 72 rpm. The amount of formulation blend in each
capsule was adjusted to 33 ± 1 mg. All filled capsules were
stored for 24 h to decrease electrostatic forces prior to them
being used in the deposition study. This 33 mg corresponds to
a theoretical dosage of 482 ± 1.5 μg of SS per single unit.
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Differential scanning calorimetry analysis
To perform thermal analysis, Perkin Elmer’s (Shelton,
Connecticut, USA) differential scanning calorimetry (DSC)
4000 equipped with a standard single-furnace was used. A
known protocol was used [22], which includes using a tem-
perature range of 25–300 °C (this range can cover all thermal
events associated with lactose) while increasing the tempera-
ture at a rate of 10 °C/min. All samples were run under N2 gas,
which allows for the samples to be purged, at a rate of 50 mL/
min. Each of the samples was accurately weighed, where the
mass ranged from 4 to 5 mg per sample on aluminum pans and
sealed with an aluminum cap. Calibration was completed
through the use of indium and zinc prior to any DSC run.
All DSC traces were analyzed in terms of melting point and
enthalpy with the accompanied Pyris Series software.
Powder X-ray diffraction
Determining particle solid state was aided by the use of
Siemens’ Diffractometer D5000 (Munich, Germany), and
the implementation of a revised methodology of Kaialy et al.
[23], where 200 mg of each carrier was placed on a holder
such that a leveled surface was obtained when observed in
comparison to the pan and diffractometer. The holder was then
placed on the diffractometer in a manner where analysis at a
specific angle was possible. The sample was exposed to CuКα
X-rays with a voltage of 40 kVand a current of 30 mAwhile
being scanned from 5° to 50° on the 2θ plane at a scanning
rate of 0.1 increments per second.
Fourier transform infrared spectroscopy
To evaluate any interaction between the carriers and leucine at
the molecular level, Perkin Elmer Spectrum One FT-IR
Spectrometer (Shelton, Connecticut, USA) equipped with a
universal ATR sampling accessory was used. Prior to analysis,
methanol was used to clean the areas susceptible to leftover
debris, after which a few milligrams of each of the carriers
were used with a pressure of 100 bar. Each of the samples was
scanned three times over a range of 4000 to 500 cm−1 to obtain
spectra with appropriate resolution; no sample preparation
was needed as the samples were analyzed as is.
Scanning electron microscope
Electron micrographs were obtained using the JMS-820 scan-
ning microscope (Freising, Germany) with a voltage of 4 kV
as such approach allowed for the evaluation and characteriza-
tion of particle morphology, size, shape, and presence or ab-
sence of agglomerates [24, 25]. Prior to taking images, each of
the carriers was placed on double-sided carbon tape where the
samples were coated for 5 min, under vacuum (in a closed
system), with gold in an argon atmosphere to prevent their
melting under the examination. To investigate the morphology
of the carriers, different magnifications (refer to SEM images)
were employed.
Homogeneity assessment
To assess the uniformity of salbutamol sulfate in each of the
formulations, 10 different samples (10–12 mg) were taken
from each of the formulations in an ordered fashion; eight
out of the 10 simulated a circle, while the ninth and tenth
samples were directly obtained from the middle. The selected
samples were dissolved in 100 mL of distilled water before
HPLC analysis was completed, as explained below. The per-
centage potency and CV% of each formulation were
calculated.
Deposition study
AMulti-Stage Liquid Impinger (MSLI), equipped with a USP
induction port (Copley Scientific in Nottingham, UK), was
used alongside the critical flow controller (Copley TPK) and
a high-capacity pump (Copley HCP5) allowing for a 4-kPa
pressure drop to be observed. The MSLI has the capacity to
filter particles, allowing for cutoff diameters to be taken into
account in each of the individual stages when it is operated
with a known flow rate. Calculating the cutoff diameter at a
different flow rate is determined using Eq. 2 [26]:
D50;Q ¼ D50;QN
ffiffiffiffiffiffiffiffiffi
QN=Q
q
ð2Þ
where D50,Q refers to the cutoff diameter at the flow rate of
Q, andN refers to the values obtained for each individual stage
of the MSLI when the flow rate is 60 L/min. As a result, when
such flow rate is used, the cutoff diameters for each of the
individual stages become 13.00, 6.80, 3.10, and 1.70 μm, re-
spectively. Furthermore, at the flow rate of 100 L/min, the
cutoff diameters change and become 10.07, 5.27, 2.40, and
1.32 μm, respectively.
Each deposition study used 10 capsules per run, where
every capsule was filled with 33 ± 1 mg of the carrier: SS
(formulation) being investigated corresponding to the theoret-
ical API dose of 482 ± 1.5 μg of salbutamol sulfate per cap-
sule. The deposition test was repeated three times for each
formulation, corresponding to 30 capsules per formulation.
In addition, specific parameters were employed for the
analysis of the aerosolization performance of each formulation
including the recovery dose (RD), emitted dose (ED), percent
recovery, percent emission, impaction loss, mass median aero-
dynamic diameter (MMAD), geometric standard deviation
(GSD), fine particle fraction (FPF), fine particle dose (FPD),
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drug loss (DL), dispersibility (DS), and effective inhalation
index (EI).
Additionally, RD is defined as the amount of drug (in μg)
recovered from the inhaler, induction port (IP), mouthpiece
(M), and stages 1–5 (S1–S5); ED as the amount of drug (in
μg) recovered from IP and S1–S5; percent recovery as the
ratio of RD to the theoretical dose (482 ± 1.5 μg); percent
emission as the ratio of ED to RD; impaction loss as the mass
fraction of drug in IP and S1 to RD (IP + S1: RD); MMAD as
the logarithmic function of the cutoff diameter to the corre-
sponding concentrations of particles found within each stage
of the MSLI; GSD as the square root of the 84th and 15th
percentiles; FPF as the ratio between FPD to RD; FPD as the
sum of drug (in μg) from S3–5; DL as the ratio of the amount
of salbutamol sulfate recovered from capsules, mouthpiece,
and inhaler to RD [(capsules + (I + M)): RD]; and DS as the
ratio of FPD to ED (FPD:ED).
Moreover, to determine the effective inhalation index (EI)
of each formulation, Eq. 3 was implemented where EI refers
to the effective inhalation index, and EM and FPF are the
percent emission and fine particle fraction [27].
EI ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
EM þ FPFð Þ
p
ð3Þ
All the deposition studies were conducted in an air-
conditioned laboratory where the temperature was 20 °C and
the relative humidity (RH) was 50%.
High-pressure liquid chromatography
To quantify salbutamol sulfate in the homogeneity test or
deposition study, a mobile phase containing 95% (v/v) of
25 mM potassium phosphate (monobasic) pH 3.0 and 5%
(v/v) of methanol was used. The flow rate of the mobile
phase through the HPLC column was 1.5 mL/min with a
total run time of 25 min per injection set at a wavelength
of 225 nm yielding a retention time of 12 min. To adjust
the pH to 3.0, a 1 M HCl solution was used while stirring
at 180 rpm, after which the mobile phase was filtered and
degassed using a Fisher Scientific (Leicestershire,
England) 0.22-μm filter before its use.
HPLC was executed via the Agilent 1100 series HPLC
system (Santa Clara, California, USA) where a degasser
(G1322A), binary pump (G1312A), variable wavelength de-
tector (VWD G1314A), column thermostat (G1316A), and
thermostatic autosampler (ALS G1329A) coupled with the
Waters Spherisorb 5 μm ODS2 4.6 × 150 mm analytical col-
umn (Milford, Massachusetts, USA). Likewise, internal stan-
dards of varying salbutamol sulfate concentrations (0.00. 0.50,
2.50, and 5.00μg/mL, respectively) were used to calibrate and
normalize the results.
Results and discussion
Particle size analysis
Figure 1 shows two cumulative particle size distribution
(PSD) diagrams that illustrate each of the carrier’s PSD when
using the (A) dry system and when using the (B) wet system.
Moreover, given the use of the Mini Spray Dryer B-290, it
was expected to obtain particle sizes that were below that of
the 63–90-μm range (Fig. 1a), given that the spray-drying
process produces particles below such range [28].
Likewise, Fig. 1b shows that the particle sizes of each of
the carriers, when using the wet system, fell within the 63–
90-μm range. The known occurrence of agglomeration was
exploited in such a manner that allowed for it to be used as a
carrier within this overall study. Such focus offered the oppor-
tunity to investigate the agglomerates on the basis of parame-
ters that are used in the characterization and analysis of single
particles. Particle size measurement in the dry systemwas able
to break the aggregates of spray-dried particles (due to apply-
ing a pressure of 3 bar during the measurement) whereas in the
wet system the spray-dried particles stayed as aggregates, al-
though the ultrasound was applied during the measurement.
Relatedly, Table 1 highlights each of the carrier’s dis-
tinct characteristics such as volume mean diameter (VMD)
and span of the RODOS dry system and the CUVETTE
wet system comparing each characteristic side by side.
Table 1 shows that all of the carriers experienced a signif-
icant difference in their VMDs when comparing each sys-
tem to one another. For the dry system, the VMD ranged
from 8.39 ± 0.40 to 37.97 ± 0.08 μm whereas the range for
the wet system was 79.31 ± 2.19 to 87.95 ± 1.91 μm due to
the presence of aggregated particles. The dry system expe-
rienced a particle diameter range of 1.56 ± 0.05 μm (D10%)
to 75.46 ± 7.22 μm (D90%) whereas the particle diameter
range for the wet system fell between 20.77 ± 11.02 μm
(D10%) and 147.87 ± 170.11 μm (D90%). Due to the aggre-
gation of particles, samples that were measured through the
wet system showed smaller span values (narrower distribu-
tion) compared to that of the dry system, coinciding with
the possibility of the dry system containing mixtures of
aggregated and de-aggregated spray-dried particles during
the measurement (Table 1).
Such outcomes, then, allowed for the carriers to be imple-
mented and further studied to determine their physicochemi-
cal properties and particle morphology given that they
underwent spray-drying, known to alter such characteristics,
while also introducing L-leucine as an excipient. VMD (ob-
tained via wet method) of the formulation after mixing for
30 min with salbutamol sulfate showed that the mixing pro-
cess was unable to break down the agglomerates as the VMD
was similar to the VMD of particles before mixing. For ex-
ample, the VMD of formulations containing 0.1 and 10%
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leucine after 30 min of mixing with SS was 88.0 ± 9.62 and
71.97 ± 0.16 μm, respectively.
Figure 2 highlights the electron micrographs of each of the
carriers making it evident that all of the formulations, with
respect to their carrier, experienced some agglomeration giv-
ing way to their larger particle size, thereby supporting the
results presented in Fig. 1 and Table 1. Moreover, the SEM
micrographs also indicate, and account for, each of the car-
rier’s morphology as they show that all of them contain spher-
ical particles with some agglomerates, particularly in the cases
of 0.5% leucine (some of these agglomerated particles for
each formulation are shown by red arrows). Such irregularity
has previously been shown to bemore effective in the delivery
of salbutamol sulfate when compared to particles that are clas-
sified as being more spherical and regular in shape [22]. The
morphology of the spray-dried lactose, with increasing con-
centrations of leucine, is supported by data published by
Aquino et al. [29], where they showed that more irregular
and corrugated particles were obtained in the presence of high
concentrations of leucine. Generally, corrugated particles dis-
perse better than spherical ones as this kind of particle reduces
contact areas and decreases inter-particulate cohesion.
Fig. 1 Particle size distribution
(PSD) diagrams of each carrier
when using the a RODOS dry
system and when using the b
CUVETTE wet system; the
carriers used were spray-dried
lactose monohydrate containing
0, 0.1, 0.5, 1, 5, and 10% L-
leucine
Table 1 Particle analysis of spray-dried lactose monohydrate and spray-dried lactose monohydrate-leucine where the concentration of leucine was 0.1,
0.5, 1, 5, and 10% showing the volume mean diameter (VMD) and span when using the RODOS dry system vs. the CUVETTE wet system (mean +
standard deviation)
Formulation VMD (μm) dry system VMD (μm) wet system Span dry system Span wet system
Spray-dried lactose 37.97 ± 0.08 87.14 ± 0.35 2.12 ± 0.09 1.36 ± 0.01
0.1% L-leucine 23.95 ± 5.35 87.47 ± 4.94 3.61 ± 0.11 1.61 ± 0.14
0.5% L-leucine 11.50 ± 0.28 79.68 ± 1.78 2.67 ± 0.13 2.14 ± 0.10
1% L-leucine 8.39 ± 0.40 86.88 ± 0.84 2.57 ± 0.06 1.73 ± 0.03
5% L-leucine 13.58 ± 0.20 79.31 ± 2.19 2.62 ± 0.12 1.74 ± 0.08
10% L-leucine 17.47 ± 0.63 87.95 ± 1.91 3.10 ± 0.23 1.40 ± 0.02
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Therefore, it was expected that the formulation composition of
the leucine carrier would result with an enhanced aerosoliza-
tion performance, when compared to the carrier without leu-
cine, which, in essence, would deliver salbutamol sulfate more
poorly.
Solid-state characterization of spray-dried samples
Figure 3 shows DSC traces of L-leucine, original lactose
monohydrate, and spray-dried lactose containing 0, 0.1,
0.5, 1, 5, and 10% L-leucine indicating where water
(A) Spray Dried (B) 0.1% L-Leucine
(B) 0.5% L-Leucine (B) 1% L-Leucine 
(B) 5% L-Leucine (B) 10% L-Leucine 
Fig. 2 SEM images of a spray-
dried lactose monohydrate, spray-
dried lactose containing-leucine
where leucine concentrations
were b 0.1%, c 0.5%, d 1%, e 5%,
and f 10%
Temperature (ºC) 
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a
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y
 
Fig. 3 DSC thermal peaks of L-
leucine, commercial lactose
monohydrate, spray-dried lactose
monohydrate-leucine where the
concentration of leucine were 0,
0.1, 0.5, 1, 5, and 10% w/v (where
an exothermic peak would point
up and an endothermic peak
would point down)
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evaporation, amorphous lactose recrystallization (Hc), α-
lactose melting (Hα), and β-lactose melting (Hβ) took
place. It is obvious from the figure that commercial lac-
tose monohydrate shows an endothermic peak around
149 °C, which corresponds to the evaporation of water,
followed by an exothermic peak around 171 °C, indicat-
ing the amorphous state in the sample; moreover, the en-
dothermic peak around 220 °C corresponds to the melting
of α-lactose [30] whereas any peak around 238 °C is an
indication of β-lactose in the sample.
Pure L-leucine was also tested to determine whether or not
any thermal events arose between the 25–300 °C range, which
would rule out whether such events were due to the presence
of leucine or not. No thermal events were seen within the
range where lactose thermal events occurred and the endother-
mic peak around 300 °C corresponds to the melting of leucine.
Spray-dried lactose showed three main thermal events with
the first being an exothermic peak around 170 °C, attributed
to the recrystallization of amorphous lactose to both α-lactose
and β-lactose, which was then followed by the melting of α-
lactose at around 220 °C; furthermore, the third endothermic
peak around 238 °C was an indication of β-lactose in the
sample. Moreover, spray-dried lactose did not show any
DSC traces for the water evaporation which was a similar
pattern that was observed for spray-dried lactose containing
0.1, 0.5, and 1% leucine, but with different intensities when
compared to the spray-dried carrier with no leucine. Spray-
dried formulations containing 5 and 10% L-leucine did not
show any sharp or obvious peaks for water evaporation, the
transition of amorphous lactose to crystalline lactose, and
melting of lactose. On the basis of this information, all
spray-dried carriers were considered to be in their amorphous
state as the data that was collected indicates given that a def-
inite crystalline structure was not present prior to their analysis
which would have been depicted through the emergence of the
amorphous lactose recrystallization enthalpy. Neither a recrys-
tallization nor a melting peak was observed in the 5 and 10%
L-leucine carrier, which serves as an indicator of their higher
stability against recrystallization. Such results follow similar
patterns that have been presented elsewhere [31–34] where
amorphous drug carriers were formulated in such a way as
to increase amorphous stability. To make sure spray-dried lac-
tose was in the amorphous state, a more reliable technique
(PXRD) was used.
Figure 4 contains the x-ray diffraction peaks for spray-
dried lactose monohydrate containing 0, 0.1, 0.5, 1, 5, and
10% L-leucine, which provides an insight into the polymor-
phic state of each of the carriers. A carrier’s morphology plays
an integral role in the drug delivery process that dictates
whether a formulation is deemed effective in the delivery of
the API of interest [30].
Looking at Fig. 4 more closely, it becomes evident that
all of the carriers, from each of the formulations, were
classified as being in their amorphous state given the ab-
sence of peaks (halo structure). In addition, all of the
carriers showed two distinct peaks each (2θ = 12.2° and
18.6°) that are broad and distributed over a wide range of
degrees on the 2θ plane, which also characterizes them as
being of amorphous state. Likewise, given that all of the
carriers exhibited irregular diffraction of electromagnetic
radiation when compared to pure L-leucine (XRD not
shown), it correspondingly catalogs them as amorphous
as well [35].
To further assess the solid state of each carrier within
this study and identify any interaction between lactose
and leucine at the molecular level, FT-IR spectroscopy
was implemented with the understanding that amorphous
lactose displays a distinct frequency at 1260 and at
900 cm−1, α-lactose monohydrate at 920 cm−1, and β-
lactose at 950 cm−1 [30]. Figure 5 presents the results
for the FT-IR spectra of L-leucine, spray-dried lactose
monohydrate with its different concentrations of L-leucine
(0, 0.1, 1, 5, and 10%), and further supports the fact that
the carriers are in their amorphous state as the aforemen-
tioned peaks were present. In addition, Fig. 5 also reveals
that, with the increasing concentration of L-leucine, each
0 10 20 30 40 50
2 Theta
Spray Dried Lactose
0.1% L-Leucine
0.5% L-Leucine
1% L-Leucine
5% L-Leucine
10% L-Leucine
Fig. 4 X-ray diffraction patterns
of spray-dried lactose
monohydrate and spray-dried
lactose monohydrate-leucine
where the concentrations of
leucine were 0.1, 0.5, 1, 5, and
10%
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formulation underwent a phenomenon known as Fermi
resonance where a shift in the vibrational energy causes
the spectra to have a change in its intensity and resolution
[36, 37].
Such variation within the spectra explains why the frequen-
cies that are associated to key functional groups like aromatic
C-H, alkanes, aldehydes, hydroxyl, carbonyl, ethers, and pri-
mary amines (which have frequencies at 2900, 3100–3400,
800–1400, and 3500 cm−1) become broadened or eliminated
completely.
In vitro analysis of DPI formulations
Salbutamol sulfate assessment
Performance of the drug delivery profile of salbutamol
sulfate, with respect to each of the formulations within
this overall study, is defined in Fig. 6 where the amount
of salbutamol sulfate recovered from each individual sec-
tion within the MSLI is looked with a narrower focus:
capsules (C), inhaler (I), mouthpiece (M), induction port
Wavenumber (cm-1) 
Fig. 5 FT-IR spectra of pure L-leucine, spray-dried lactose monohydrate,
and spray-dried lactose monohydrate-leucine where the concentrations of
leucine were 0.1, 0.5, 1, 5, and 10% highlighting the areas that are
eliminated or broadened as the concentration of L-leucine increases
while also showing where the amorphous, α-lactose, and β-lactose
peaks are to be found
Fig. 6 Aerosolization
performance of each of the
formulations (spray-dried lactose
monohydrate and spray-dried
lactose monohydrate-leucine
where the concentrations of
leucine were 0.1, 0.5, 1, 5, and
10% highlighting the amount of
SS recovered (percent recovered)
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(IP), stage 1, stage 2, stage 3, stage 4, and filter (stage 5).
All of the formulations experienced minimal salbutamol
sulfate deposits in the capsules with 5 and 10% L-leucine
having the least amount after their actuation due to the
lubrication effect of leucine, which makes particles flow
more easily from the capsule to the inhaler device
(Cyclohaler). The lubrication effect of the spray-dried leu-
cine has been reported where increasing amounts of L-
leucine show good lubricating properties [38]. As parti-
cles maneuver through the respiratory tract, spray-dried
lactose monohydrate along with 0.1% L-leucine experi-
enced the highest amounts of salbutamol sulfate (43.63
± 23.48 and 49.89 ± 27.80 μg, respectively) in the inhaler
device when compared to the concentrations above 0.5%
L-leucine which experienced the least amount at 13.79 ±
11.47 μg; the lubrication effect of leucine can also be
observed here, as described previously. Furthermore, all
of the formulations showed about the same amount of
salbutamol sulfate in the mouthpiece (Fig. 6) but begin
to differ at the IP as spray-dried lactose monohydrate
had the highest amount (65.24 ± 4.26 μg) when compared
to the other formulations, which had a range of 12.66 ±
5.66 to 29.02 ± 18.56 μg.
Moreover, 0.1% L-leucine had the highest salbutamol sul-
fate recovered from within stage 1 (176.06 ± 50.94 μg), but
where it began to change was with stage 2 onward as 0.5% L-
leucine experienced the highest salbutamol sulfate amounts in
stage 2, stage 3, stage 4, and filter (81.89 ± 50.20, 145.58 ±
88.08, 87.45 ± 48.49, and 29.25 ± 20.16 μg, respectively) in-
dicative of it being the most successful at delivering
salbutamol sulfate to the targeted area that correlates to the
alveoli, found in the lower respiratory tract. In other words,
the formulations ranked in the following order 0.5% L-leucine
> 0.1% L-leucine > 1% L-leucine > spray-dried lactose
monohydrate > 5% L-leucine > 10% L-leucine.
Table 2 shows the aerosolization performance and depo-
sition data for all formulations studied. The authors in the
present study were interested in looking at, namely, FPF
(fine particle fraction), DL (drug loss), impaction loss
(IL), and effective inhalation efficiency (EI). All of the for-
mulations differed remarkably from one another with re-
spect to DL and percent emission (Table 2) given that they
all undertook a high number of actuations (n = 10) per run,
with each being filled with a consistent weight of around 33
± 1 mg. The table shows that the performance of DPI for-
mulations containing spray-dried leucine is much better
than when leucine was excluded from the formulation (the
lowest drug loss belonged to spray-dried lactose containing
0.5% L-leucine).
Impact loss (IL) within the formulations varied from 34.61
± 12.38%, attributed to 0.5% L-leucine, to 52.49 ± 2.81%, be-
longing to spray-dried lactose monohydrate. Such variation
between the formulations could be attributed to their Ta
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aerodynamic diameter given that impaction is a flow-
dependent mechanism governed by particle size [39].
Effective inhalation index (EI) ranged from 10.87 ± 0.22
(spray-dried lactose monohydrate) to 11.98 ± 0.37 (0.5% L-
leucine) aligning with other data suggesting that 0.5% L-leu-
cine has a high-drug aerosolization efficiency.
DS and FPD also showed a variation among the formula-
tions with ranges of 29.31 ± 0.36 to 48.94 ± 10.78% and
262.28 ± 156.60 to 110.41 ± 4.77 μg, respectively. Such vari-
ation was attributed to the formulation’s particle size given
that the phenomenon of inertial impaction becomes prevalent
for large particles [39].
When it came to MMAD and GSD, however, all of the
formulations gave similar results with MMAD being 3.12 ±
0.10 μm and GSD being 2.12 ± 0.03 μm. Such results mean
that all of the SS was, theoretically, delivered to the area of
keen interest. It also correlates with obtaining a FPF of 100%,
which was not the case, as other factors came into play like
impaction onto the upper respiratory tract where particles
greater than or equal to 10μm are removed by the mucociliary
escalator and subsequently swallowed [40, 41].
The results showed that spray-dried lactose-leucine (con-
taining 0.5% L-leucine) exhibited the highest FPF of 47.11 ±
9.94% suggesting that such formulation was the most efficient
at delivering the most SS to the lower respiratory tract. This is
because of the correlation that is seen between FPF and
amount of SS delivered; that is to say, when FPF increases,
the expected amount of SS that is delivered to the lower re-
spiratory tract also increases [42]. Such values, when com-
pared to those obtained by Kaialy et al. [23] (FPF of 44.85
± 1.76%) and Kaialy and Nokhodchi [43] (FPF of 46.9 ±
3.6%), prove to be an increase in the efficacy of salbutamol
sulfate’s aerosolization performance. This formulation also
had the highest percent emission of 96.41 ± 1.23%, when
compared to the other formulations (Table 2), suggesting that
SS was able to detach itself from the carrier easier when com-
pared to the other formulations. This means that optimal phys-
icochemical properties were attained such that a complemen-
tary system emerged between SS and the 0.5% L-leucine
carrier. On the other hand, spray-dried lactose monohydrate
showed the lowest percent emission (87.02 ± 3.79%) and con-
sequently the lowest FPF (25.51 ± 1.23%). Such results infer
that SS had a more difficult time detaching itself from the
spray-dried lactose monohydrate carrier during inhalation
when compared to 0.5% L-leucine.
Homogeneity assessment
Assessing the homogeneity of each of the formulations
was an essential phase of this overall study given that a
uniform formulation will give rise to a more effective drug
delivery profile with a consistent dose to the patient.
Table 3 eludes the homogeneity profile of each of the for-
mulations (spray-dried lactose monohydrate, samples
spray-dried with 0.1, 0.5, 1, 5, and 10% L-leucine) under
investigation showing the potency of each and also pre-
sents the percent content homogeneity, which is expressed
as the percent coefficient of variation (%CV), of each of
the aforementioned formulations. The drug content of all
formulations was within 75–125%, and the smallest %CV
of 5.48% belonged to 0.5% L-leucine, which was the for-
mulation that showed the best aerosolization performance.
Such results indicate that 0.5% L-leucine had the best
salbutamol sulfate content homogeneity among all of the
formulations followed by 0.1% L-leucine with a %CV of
7.15%. In addition, the results showed that it is a bit diffi-
cult to obtain a very low CV% for DPI formulation con-
taining salbutamol sulfate in the DPI formulation studied
in the current research. This should be investigated more in
the future ongoing research.
Conclusion
L-Leucine’s addition allowed for the emergence of a more
effective aerosolization performance as it assisted in the alter-
ing of lactose monohydrate’s physicochemical properties in
such a way as to provide a two-fold increase in the fine particle
fraction that equates to an increase in salbutamol sulfate’s
concentration in the lower respiratory tract. In addition,
through this study, it has been proven that L-leucine improves
the stability of amorphous spray-dried lactose as was evident
fromDSC traces while simultaneously providing a lubrication
effect for the formulations that were studied.
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Table 3 Content homogeneity of spray-dried lactose monohydrate,
0.1% L-leucine, 0.5% L-leucine, 1% L-leucine, 5% L-leucine, and 10%
L-leucine expressed as the percent coefficient of variation (%CV)
Formulation Potency %CV
Spray-dried lactose 91.36 ± 9.40 10.29
0.1% L-leucine 83.62 ± 5.98 7.15
0.5% L-leucine 102.66 ± 5.62 5.48
1% L-leucine 94.72 ± 16.97 17.92
5% L-leucine 89.71 ± 11.87 13.23
10% L-leucine 89.98 ± 7.78 8.65
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